Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer
Molecular target therapy is one of the most popular field of non-small cell lung cancer (NSCLC) treatmnet. Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearragement are the most important two oncogenic drivers in NSCLC, early studies suggested that EGFR mutat...
Main Authors: | Xin WANG, Diansheng ZHONG |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2018-09-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2018.09.07 |
Similar Items
-
A New Target in Non-small Cell Lung Cancer: EML4-ALK Fusion Gene
by: Huijuan WANG, et al.
Published: (2011-06-01) -
Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma‐like carcinoma
by: Kai Yin, et al.
Published: (2020-02-01) -
The Research of Clinical Pathological Features of ALK Positive Lung Cancer
in 525 Patients and the Discussion of Detection Methods
by: Xiang ZHU, et al.
Published: (2014-03-01) -
Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer
by: Shasha WANG, et al.
Published: (2020-11-01) -
Trials to overcome drug resistance to EGFR and ALK targeted therapies - past, present and future
by: Glenwood Dillon Goss, et al.
Published: (2014-08-01)